;PMID: 2161747
;source_file_1932.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..39] = [t:0..39]
;1)sentence:[e:45..175] = [t:45..175]
;2)section:[e:179..248] = [t:179..248]
;3)section:[e:252..353] = [t:252..353]
;4)sentence:[e:357..521] = [t:357..521]
;5)sentence:[e:522..675] = [t:522..675]
;6)sentence:[e:676..795] = [t:676..795]
;7)sentence:[e:796..1162] = [t:796..1162]
;8)sentence:[e:1163..1346] = [t:1163..1346]
;9)sentence:[e:1347..1478] = [t:1347..1478]
;10)sentence:[e:1479..1627] = [t:1479..1627]
;11)sentence:[e:1628..1871] = [t:1628..1871]
;12)sentence:[e:1872..2083] = [t:1872..2083]
;13)sentence:[e:2084..2390] = [t:2084..2390]
;14)section:[e:2394..2438] = [t:2394..2438]

;section 0 Span:0..39
;Endocrinology. 1990 Jun;126(6):3089-95.
(SEC
  (FRAG (NNP:[0..13] Endocrinology) (,:[13..14] .) (CD:[15..19] 1990)
        (.:[20..27] Jun;126) (-LRB-:[27..28] -LRB-) (CD:[28..29] 6)
        (-RRB-:[29..30] -RRB-) (::[30..31] :) (CD:[31..35] 3089) (::[35..36] -)
        (CD:[36..38] 95) (.:[38..39] .)))

;sentence 1 Span:45..175
;Basic fibroblast growth factor inhibits gonadotropin-supported ovarian
;androgen  biosynthesis: mechanism(s) and site(s) of action.
;[45..75]:substance:"Basic fibroblast growth factor"
;[85..97]:substance:"gonadotropin"
;[116..124]:substance:"androgen"
(SENT
  (FRAG-HLN
    (S
      (NP-SBJ (JJ:[45..50] Basic) (NN:[51..61] fibroblast) (NN:[62..68] growth)
              (NN:[69..75] factor))
      (VP (VBZ:[76..84] inhibits)
        (NP
          (ADJP (NN:[85..97] gonadotropin) (HYPH:[97..98] -)
                (VBN:[98..107] supported))
          (JJ:[108..115] ovarian) (NN:[116..124] androgen)
           (NN:[126..138] biosynthesis))))
    (::[138..139] :)
    (NP
      (NP (NN:[140..152] mechanism-LRB-s-RRB-) (CC:[153..156] and)
          (NN:[157..164] site-LRB-s-RRB-))
      (PP (IN:[165..167] of)
        (NP (NN:[168..174] action))))
    (.:[174..175] .)))

;section 2 Span:179..248
;Hurwitz A, Hernandez ER, Resnick CE, Packman JN, Payne DW, Adashi EY.
(SEC
  (FRAG (NNP:[179..186] Hurwitz) (NNP:[187..188] A) (,:[188..189] ,)
        (NNP:[190..199] Hernandez) (NN:[200..202] ER) (,:[202..203] ,)
        (NNP:[204..211] Resnick) (NNP:[212..214] CE) (,:[214..215] ,)
        (NNP:[216..223] Packman) (NNP:[224..226] JN) (,:[226..227] ,)
        (NNP:[228..233] Payne) (NNP:[234..236] DW) (,:[236..237] ,)
        (NNP:[238..244] Adashi) (NNP:[245..247] EY) (.:[247..248] .)))

;section 3 Span:252..353
;Department of Obstetrics and Gynecology, University of Maryland School of 
;Medicine, Baltimore 21201.
(SEC
  (FRAG (NNP:[252..262] Department) (IN:[263..265] of)
        (NNP:[266..276] Obstetrics) (CC:[277..280] and)
        (NNP:[281..291] Gynecology) (,:[291..292] ,) (NNP:[293..303] University)
        (IN:[304..306] of) (NNP:[307..315] Maryland) (NNP:[316..322] School)
        (IN:[323..325] of) (NNP:[327..335] Medicine) (,:[335..336] ,)
        (NNP:[337..346] Baltimore) (CD:[347..352] 21201) (.:[352..353] .)))

;sentence 4 Span:357..521
;Current evidence favors the hypothesis that granulosa cell-derived basic 
;fibroblast growth factor (bFGF) may be the centerpiece of an intraovarian 
;autocrine loop.
;[424..455]:substance:"basic  fibroblast growth factor"
;[457..461]:substance:"bFGF"
(SENT
  (S
    (NP-SBJ (JJ:[357..364] Current) (NN:[365..373] evidence))
    (VP (VBZ:[374..380] favors)
      (NP (DT:[381..384] the) (NN:[385..395] hypothesis)
        (SBAR (IN:[396..400] that)
          (S
            (NP-SBJ
              (ADJP
                (NML (NN:[401..410] granulosa) (NN:[411..415] cell))
                (HYPH:[415..416] -) (VBN:[416..423] derived))
              (NML
                (NML (JJ:[424..429] basic) (NN:[431..441] fibroblast)
                     (NN:[442..448] growth) (NN:[449..455] factor))
                (NML (-LRB-:[456..457] -LRB-) (NN:[457..461] bFGF)
                     (-RRB-:[461..462] -RRB-))))
            (VP (MD:[463..466] may)
              (VP (VB:[467..469] be)
                (NP-PRD
                  (NP (DT:[470..473] the) (NN:[474..485] centerpiece))
                  (PP (IN:[486..488] of)
                    (NP (DT:[489..491] an) (JJ:[492..504] intraovarian)
                        (JJ:[506..515] autocrine) (NN:[516..520] loop))))))))))
    (.:[520..521] .)))

;sentence 5 Span:522..675
;In this report we examine the possibility that bFGF may also be  involved in
;paracrine interactions at the level of the ovarian  theca-interstitial cell.
;[569..573]:substance:"bFGF"
(SENT
  (S
    (PP-LOC (IN:[522..524] In)
      (NP (DT:[525..529] this) (NN:[530..536] report)))
    (NP-SBJ (PRP:[537..539] we))
    (VP (VBP:[540..547] examine)
      (NP (DT:[548..551] the) (NN:[552..563] possibility)
        (SBAR (IN:[564..568] that)
          (S
            (NP-SBJ-1 (NN:[569..573] bFGF))
            (VP (MD:[574..577] may)
              (ADVP (RB:[578..582] also))
              (VP (VB:[583..585] be)
                (VP (VBN:[587..595] involved)
                  (NP-1 (-NONE-:[595..595] *))
                  (PP-CLR (IN:[596..598] in)
                    (NP (JJ:[599..608] paracrine) (NNS:[609..621] interactions)))
                  (PP (IN:[622..624] at)
                    (NP
                      (NP (DT:[625..628] the) (NN:[629..634] level))
                      (PP (IN:[635..637] of)
                        (NP (DT:[638..641] the)
                          (ADJP
                            (NML (JJ:[642..649] ovarian) (NN:[651..656] theca))
                            (HYPH:[656..657] -) (JJ:[657..669] interstitial))
                          (NN:[670..674] cell))))))))))))
    (.:[674..675] .)))

;sentence 6 Span:676..795
;To this end, whole ovarian dispersates obtained from  immature rats were
;cultured for 96 h under serum-free conditions.
;[762..764]:quantitative-value:"96"
;[765..766]:quantitative-units:"h"
(SENT
  (S
    (PP (TO:[676..678] To)
      (NP (DT:[679..683] this) (NN:[684..687] end)))
    (,:[687..688] ,)
    (NP-SBJ-1
      (NP (JJ:[689..694] whole) (JJ:[695..702] ovarian)
          (NNS:[703..714] dispersates))
      (VP (VBN:[715..723] obtained)
        (NP (-NONE-:[723..723] *))
        (PP-CLR (IN:[724..728] from)
          (NP (JJ:[730..738] immature) (NNS:[739..743] rats)))))
    (VP (VBD:[744..748] were)
      (VP (VBN:[749..757] cultured)
        (NP-1 (-NONE-:[757..757] *))
        (PP-TMP (IN:[758..761] for)
          (NP (CD:[762..764] 96) (NN:[765..766] h)))
        (PP-MNR (IN:[767..772] under)
          (NP
            (ADJP (NN:[773..778] serum) (HYPH:[778..779] -) (JJ:[779..783] free))
            (NNS:[784..794] conditions)))))
    (.:[794..795] .)))

;sentence 7 Span:796..1162
;The  accumulation of androsterone, the major androgenic steroid detected,
;increased  3- to 5-fold over baseline in response to treatment with hCG (1
;ng/ml), an  effect further optimized (2- to 4-fold) by supplementation with
;insulin-like  growth factor-I (10 ng/ml), insulin (1 microgram/ml),
;terbutaline (10(-6) M), or  high density lipoprotein (100 micrograms/ml).
;[817..829]:substance:"androsterone"
;[841..859]:substance:"androgenic steroid"
;[881..893]:quantitative-value:"3- to 5-fold"
;[938..941]:substance:"hCG"
;[943..944]:quantitative-value:"1"
;[945..950]:quantitative-units:"ng/ml"
;[983..995]:quantitative-value:"2- to 4-fold"
;[1021..1050]:substance:"insulin-like  growth factor-I"
;[1052..1054]:quantitative-value:"10"
;[1055..1060]:quantitative-units:"ng/ml"
;[1063..1070]:substance:"insulin"
;[1072..1073]:quantitative-value:"1"
;[1074..1086]:quantitative-units:"microgram/ml"
;[1089..1100]:substance:"terbutaline"
;[1102..1108]:quantitative-value:"10(-6)"
;[1109..1110]:quantitative-units:"M"
;[1130..1141]:substance:"lipoprotein"
;[1143..1146]:quantitative-value:"100"
;[1147..1160]:quantitative-units:"micrograms/ml"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[796..799] The) (NN:[801..813] accumulation))
      (PP (IN:[814..816] of)
        (NP
          (NP (NN:[817..829] androsterone))
          (,:[829..830] ,)
          (NP
            (NP (DT:[831..834] the) (JJ:[835..840] major)
               (JJ:[841..851] androgenic) (NN:[852..859] steroid))
            (VP (VBN:[860..868] detected)
              (NP (-NONE-:[868..868] *)))))))
    (,:[868..869] ,)
    (VP (VBD:[870..879] increased)
      (ADVP-EXT
        (QP (CD:[881..882] 3) (HYPH:[882..883] -) (TO:[884..886] to)
            (CD:[887..888] 5) (HYPH:[888..889] -) (RB:[889..893] fold))
        (PP (IN:[894..898] over)
          (NP (NN:[899..907] baseline))))
      (PP (IN:[908..910] in)
        (NP
          (NP (NN:[911..919] response))
          (PP (TO:[920..922] to)
            (NP
              (NP (NN:[923..932] treatment))
              (PP (IN:[933..937] with)
                (NP
                  (NP (NN:[938..941] hCG))
                  (PRN (-LRB-:[942..943] -LRB-)
                    (NP
                      (NP (CD:[943..944] 1) (NN:[945..947] ng))
                      (PP (SYM:[947..948] /)
                        (NP (NN:[948..950] ml))))
                    (-RRB-:[950..951] -RRB-))))))))
      (,:[951..952] ,)
      (NP
        (NP (DT:[953..955] an) (NN:[957..963] effect))
        (VP
          (ADVP (RB:[964..971] further))
          (VBN:[972..981] optimized)
          (NP (-NONE-:[981..981] *))
          (PRN (-LRB-:[982..983] -LRB-)
            (ADVP
              (QP (CD:[983..984] 2) (HYPH:[984..985] -) (TO:[986..988] to)
                  (CD:[989..990] 4))
              (HYPH:[990..991] -) (RB:[991..995] fold))
            (-RRB-:[995..996] -RRB-))
          (PP-MNR (IN:[997..999] by)
            (NP (NN:[1000..1015] supplementation)
              (PP (IN:[1016..1020] with)
                (NP
                  (NP
                    
                    (ADJP (NN:[1021..1028] insulin) (HYPH:[1028..1029] -)
                          (JJ:[1029..1033] like))
                    (NN:[1035..1041] growth) (NN:[1042..1050] factor-I)
                    (PRN (-LRB-:[1051..1052] -LRB-)
                      (NP
                        (NP (CD:[1052..1054] 10) (NN:[1055..1057] ng))
                        (PP (SYM:[1057..1058] /)
                          (NP (NN:[1058..1060] ml))))
                      (-RRB-:[1060..1061] -RRB-)))
                  (,:[1061..1062] ,)
                  (NP
                    (NP (NN:[1063..1070] insulin))
                    (PRN (-LRB-:[1071..1072] -LRB-)
                      (NP
                        (NP (CD:[1072..1073] 1) (NN:[1074..1083] microgram))
                        (PP (SYM:[1083..1084] /)
                          (NP (NN:[1084..1086] ml))))
                      (-RRB-:[1086..1087] -RRB-)))
                  (,:[1087..1088] ,)
                  (NP (NN:[1089..1100] terbutaline)
                    (PRN (-LRB-:[1101..1102] -LRB-)
                      (NP (CD:[1102..1108] 10-LRB--6-RRB-) (NN:[1109..1110] M))
                      (-RRB-:[1110..1111] -RRB-)))
                  (,:[1111..1112] ,) (CC:[1113..1115] or)
                  (NP
                    (NML (JJ:[1117..1121] high) (NN:[1122..1129] density))
                    (NN:[1130..1141] lipoprotein)
                    (PRN (-LRB-:[1142..1143] -LRB-)
                      (NP
                        (NP (CD:[1143..1146] 100) (NNS:[1147..1157] micrograms))
                        (PP (SYM:[1157..1158] /)
                          (NP (NN:[1158..1160] ml))))
                      (-RRB-:[1160..1161] -RRB-))))))))))
    (.:[1161..1162] .)))

;sentence 8 Span:1163..1346
;In the absence of these optimizing  supplements, bFGF was without effect on
;basal androsterone accumulation, but  produced a relatively modest (20%)
;inhibition of hCG hormonal action.
;[1212..1216]:substance:"bFGF"
;[1245..1257]:substance:"androsterone"
;[1307..1310]:quantitative-value:"20%"
;[1326..1329]:substance:"hCG"
(SENT
  (S
    (PP (IN:[1163..1165] In)
      (NP
        (NP (DT:[1166..1169] the) (NN:[1170..1177] absence))
        (PP (IN:[1178..1180] of)
          (NP (DT:[1181..1186] these) (VBG:[1187..1197] optimizing)
              (NNS:[1199..1210] supplements)))))
    (,:[1210..1211] ,)
    (NP-SBJ (NN:[1212..1216] bFGF))
    (VP
      (VP (VBD:[1217..1220] was)
        (PP-PRD (IN:[1221..1228] without)
          (NP (NN:[1229..1235] effect)))
        (PP (IN:[1236..1238] on)
          (NP (JJ:[1239..1244] basal) (NN:[1245..1257] androsterone)
              (NN:[1258..1270] accumulation))))
      (,:[1270..1271] ,) (CC:[1272..1275] but)
      (VP (VBD:[1277..1285] produced)
        (NP
          (NP (DT:[1286..1287] a)
            (ADJP (RB:[1288..1298] relatively) (JJ:[1299..1305] modest)
              (PRN (-LRB-:[1306..1307] -LRB-)
                (NP (CD:[1307..1309] 20) (NN:[1309..1310] %))
                (-RRB-:[1310..1311] -RRB-)))
            (NN:[1312..1322] inhibition))
          (PP (IN:[1323..1325] of)
            (NP (NN:[1326..1329] hCG) (JJ:[1330..1338] hormonal)
                (NN:[1339..1345] action))))))
    (.:[1345..1346] .)))

;sentence 9 Span:1347..1478
;In  contrast, bFGF proved a highly potent inhibitor (80%) of hCG-stimulated
;androgen  biosynthesis in supplement-enriched cultures.
;[1361..1365]:substance:"bFGF"
;[1389..1398]:substance:"inhibitor"
;[1400..1403]:quantitative-value:"80%"
;[1408..1411]:substance:"hCG"
;[1423..1431]:substance:"androgen"
(SENT
  (S
    (PP (IN:[1347..1349] In)
      (NP (NN:[1351..1359] contrast)))
    (,:[1359..1360] ,)
    (NP-SBJ (NN:[1361..1365] bFGF))
    (VP (VBD:[1366..1372] proved)
      (NP-PRD
        (NP (DT:[1373..1374] a)
          (ADJP (RB:[1375..1381] highly) (JJ:[1382..1388] potent))
          (NN:[1389..1398] inhibitor)
          (PRN (-LRB-:[1399..1400] -LRB-)
            (NP (CD:[1400..1402] 80) (NN:[1402..1403] %))
            (-RRB-:[1403..1404] -RRB-)))
        (PP (IN:[1405..1407] of)
          (NP
            (ADJP (NN:[1408..1411] hCG) (HYPH:[1411..1412] -)
                  (VBN:[1412..1422] stimulated))
            (NN:[1423..1431] androgen) (NN:[1433..1445] biosynthesis))))
      (PP-LOC (IN:[1446..1448] in)
        (NP
          (ADJP (NN:[1449..1459] supplement) (HYPH:[1459..1460] -)
                (VBN:[1460..1468] enriched))
          (NNS:[1469..1477] cultures))))
    (.:[1477..1478] .)))

;sentence 10 Span:1479..1627
;This reversible bFGF action proved  to be time and dose dependent, with a
;minimal time requirement of 48 h and a  median inhibitory dose of 2 ng/ml.
;[1495..1499]:substance:"bFGF"
;[1581..1583]:quantitative-value:"48"
;[1584..1585]:quantitative-units:"h"
;[1619..1620]:quantitative-value:"2"
;[1621..1626]:quantitative-units:"ng/ml"
(SENT
  (S
    (NP-SBJ-2 (DT:[1479..1483] This) (JJ:[1484..1494] reversible)
              (NN:[1495..1499] bFGF) (NN:[1500..1506] action))
    (VP (VBD:[1507..1513] proved)
      (S
        (NP-SBJ-2 (-NONE-:[1513..1513] *))
        (VP (TO:[1515..1517] to)
          (VP (VB:[1518..1520] be)
            (ADJP-PRD
              (ADJP (NN:[1521..1525] time)
                (ADJP-1 (-NONE-:[1525..1525] *P*)))
              (CC:[1526..1529] and)
              (ADJP (NN:[1530..1534] dose)
                (ADJP-1 (JJ:[1535..1544] dependent))))
            (,:[1544..1545] ,)
            (PP (IN:[1546..1550] with)
              (NP
                (NP
                  (NP (DT:[1551..1552] a) (JJ:[1553..1560] minimal)
                      (NN:[1561..1565] time) (NN:[1566..1577] requirement))
                  (PP (IN:[1578..1580] of)
                    (NP (CD:[1581..1583] 48) (NN:[1584..1585] h))))
                (CC:[1586..1589] and)
                (NP
                  (NP (DT:[1590..1591] a) (JJ:[1593..1599] median)
                      (JJ:[1600..1610] inhibitory) (NN:[1611..1615] dose))
                  (PP (IN:[1616..1618] of)
                    (NP
                      (NP (CD:[1619..1620] 2) (NN:[1621..1623] ng))
                      (PP (SYM:[1623..1624] /)
                        (NP (NN:[1624..1626] ml))))))))))))
    (.:[1626..1627] .)))

;sentence 11 Span:1628..1871
;Unaccounted for by altered (hCG-stimulated)  cAMP generation or a diminution
;in the viable cell mass, the antigonadotropic  effect of bFGF may by
;inference be assumed to involve a site(s) of action distal  to or independent
;of cAMP generation.
;[1656..1659]:substance:"hCG"
;[1673..1677]:substance:"cAMP"
;[1762..1766]:substance:"bFGF"
;[1855..1859]:substance:"cAMP"
(SENT
  (S
    (S-ADV
      (NP-SBJ (-NONE-:[1628..1628] *))
      (ADJP-PRD (JJ:[1628..1639] Unaccounted)
        (PP (IN:[1640..1643] for)
          (PP (IN:[1644..1646] by)
            (NP
              (NP (VBN:[1647..1654] altered)
                (PRN (-LRB-:[1655..1656] -LRB-)
                  (ADJP (NN:[1656..1659] hCG) (HYPH:[1659..1660] -)
                        (VBN:[1660..1670] stimulated))
                  (-RRB-:[1670..1671] -RRB-))
                (NN:[1673..1677] cAMP) (NN:[1678..1688] generation))
              (CC:[1689..1691] or)
              (NP
                (NP (DT:[1692..1693] a) (NN:[1694..1704] diminution))
                (PP (IN:[1705..1707] in)
                  (NP (DT:[1708..1711] the) (JJ:[1712..1718] viable)
                      (NN:[1719..1723] cell) (NN:[1724..1728] mass)))))))))
    (,:[1728..1729] ,)
    (NP-SBJ-2
      (NP (DT:[1730..1733] the) (JJ:[1734..1750] antigonadotropic)
          (NN:[1752..1758] effect))
      (PP (IN:[1759..1761] of)
        (NP (NN:[1762..1766] bFGF))))
    (VP (MD:[1767..1770] may)
      (PP (IN:[1771..1773] by)
        (NP (NN:[1774..1783] inference)))
      (VP (VB:[1784..1786] be)
        (ADJP-PRD (VBN:[1787..1794] assumed)
          (S
            (NP-SBJ-2 (-NONE-:[1794..1794] *))
            (VP (TO:[1795..1797] to)
              (VP (VB:[1798..1805] involve)
                (NP
                  (NP
                    (NP (DT:[1806..1807] a) (NN:[1808..1815] site-LRB-s-RRB-))
                    (PP (IN:[1816..1818] of)
                      (NP (NN:[1819..1825] action))))
                  (ADJP
                    (ADJP (JJ:[1826..1832] distal)
                      (PP (TO:[1834..1836] to)
                        (NP-1 (-NONE-:[1836..1836] *RNR*))))
                    (CC:[1837..1839] or)
                    (ADJP (JJ:[1840..1851] independent)
                      (PP (IN:[1852..1854] of)
                        (NP-1 (-NONE-:[1854..1854] *RNR*))))
                    (NP-1 (NN:[1855..1859] cAMP) (NN:[1860..1870] generation))))))))))
    (.:[1870..1871] .)))

;sentence 12 Span:1872..2083
;In this connection, cellular radiolabeling  with [3H] pregnanolone (3
;alpha-hydroxy-5 alpha-pregnane-20-one) revealed bFGF  to be a potent
;inhibitor of the steroidogenic enzyme 17  alpha-hydroxylase/17-20-lyase.
;[1921..1938]:substance:"[3H] pregnanolone"
;[1940..1979]:substance:"3 alpha-hydroxy-5 alpha-pregnane-20-one"
;[1990..1994]:substance:"bFGF"
;[2011..2020]:substance:"inhibitor"
;[2028..2048]:substance:"steroidogenic enzyme"
;[2049..2070]:cyp450:"17  alpha-hydroxylase"
;[2071..2082]:cyp450:"17-20-lyase"
(SENT
  (S
    (PP (IN:[1872..1874] In)
      (NP (DT:[1875..1879] this) (NN:[1880..1890] connection)))
    (,:[1890..1891] ,)
    (NP-SBJ
      (NP (JJ:[1892..1900] cellular) (NN:[1901..1914] radiolabeling))
      (PP (IN:[1916..1920] with)
        (NP
          (NP
            (NML (-LRB-:[1921..1922] -LSB-) (NN:[1922..1924] 3H)
                 (-RRB-:[1924..1925] -RSB-))
            (NN:[1926..1938] pregnanolone))
          (NP (-LRB-:[1939..1940] -LRB-)
             (CD:[1940..1941] 3) (NN:[1942..1957] alpha-hydroxy-5)
             (NN:[1958..1979] alpha-pregnane-20-one)
            (-RRB-:[1979..1980] -RRB-)))))
    (VP (VBD:[1981..1989] revealed)
      (S
        (NP-SBJ (NN:[1990..1994] bFGF))
        (VP (TO:[1996..1998] to)
          (VP (VB:[1999..2001] be)
            (NP-PRD
              (NP (DT:[2002..2003] a) (JJ:[2004..2010] potent)
                  (NN:[2011..2020] inhibitor))
              (PP (IN:[2021..2023] of)
                (NP
                  (NP (DT:[2024..2027] the)
                     (JJ:[2028..2041] steroidogenic) (NN:[2042..2048] enzyme))
                  (NP
                     (CD:[2049..2051] 17) (NN:[2053..2070] alpha-hydroxylase)
                    (SYM:[2070..2071] /) (NN:[2071..2082] 17-20-lyase)))))))))
    (.:[2082..2083] .)))

;sentence 13 Span:2084..2390
;As such, these findings are in keeping with the  possibility that locally
;derived bFGF may exert a dual inhibitory action on  (mature) ovarian estrogen
;production by reducing androgen substrate provision as  well as by exercising
;its now established ability to attenuate granulosa cell  aromatase activity.
;[2166..2170]:substance:"bFGF"
;[2227..2235]:substance:"estrogen"
;[2259..2267]:substance:"androgen"
;[2268..2277]:substance:"substrate"
;[2371..2380]:substance:"aromatase"
(SENT
  (S
    (PP (IN:[2084..2086] As)
      (NP (JJ:[2087..2091] such)))
    (,:[2091..2092] ,)
    (NP-SBJ (DT:[2093..2098] these) (NNS:[2099..2107] findings))
    (VP (VBP:[2108..2111] are)
      (PP-PRD (IN:[2112..2114] in)
        (S-NOM
          (NP-SBJ (-NONE-:[2114..2114] *))
          (VP (VBG:[2115..2122] keeping)
            (PP (IN:[2123..2127] with)
              (NP (DT:[2128..2131] the) (NN:[2133..2144] possibility)
                (SBAR (IN:[2145..2149] that)
                  (S
                    (NP-SBJ
                      (ADJP (RB:[2150..2157] locally) (VBN:[2158..2165] derived))
                      (NN:[2166..2170] bFGF))
                    (VP (MD:[2171..2174] may)
                      (VP (VB:[2175..2180] exert)
                        (NP
                          (NP (DT:[2181..2182] a) (JJ:[2183..2187] dual)
                              (JJ:[2188..2198] inhibitory)
                              (NN:[2199..2205] action))
                          (PP (IN:[2206..2208] on)
                            (NP
                              (PRN (-LRB-:[2210..2211] -LRB-)
                                (ADJP (JJ:[2211..2217] mature))
                                (-RRB-:[2217..2218] -RRB-))
                              (JJ:[2219..2226] ovarian)
                               (NN:[2227..2235] estrogen)
                               (NN:[2236..2246] production)))))))))))))
      (PP-MNR
        (PP (IN:[2247..2249] by)
          (S-NOM
            (NP-SBJ (-NONE-:[2249..2249] *))
            (VP (VBG:[2250..2258] reducing)
              (NP (NN:[2259..2267] androgen) (NN:[2268..2277] substrate)
                  (NN:[2278..2287] provision)))))
        (CONJP (RB:[2288..2290] as) (RB:[2292..2296] well) (IN:[2297..2299] as))
        (PP (IN:[2300..2302] by)
          (S-NOM
            (NP-SBJ (-NONE-:[2302..2302] *))
            (VP (VBG:[2303..2313] exercising)
              (NP (PRP$:[2314..2317] its)
                (ADJP (RB:[2318..2321] now) (VBN:[2322..2333] established))
                (NN:[2334..2341] ability)
                (S
                  (NP-SBJ (-NONE-:[2341..2341] *))
                  (VP (TO:[2342..2344] to)
                    (VP (VB:[2345..2354] attenuate)
                      (NP
                        (NML (NN:[2355..2364] granulosa) (NN:[2365..2369] cell))
                        (NN:[2371..2380] aromatase) (NN:[2381..2389] activity)))))))))))
    (.:[2389..2390] .)))

;section 14 Span:2394..2438
;PMID: 2161747 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2394..2398] PMID) (::[2398..2399] :) (CD:[2400..2407] 2161747)
        (NN:[2408..2409] -LSB-) (NNP:[2409..2415] PubMed) (::[2416..2417] -)
        (NN:[2418..2425] indexed) (IN:[2426..2429] for)
        (NNP:[2430..2438] MEDLINE-RSB-)))
